Clinical Trial Search

Primary: Change From Baseline in Body Weight — -1.41; -0.91; -1.66 kg — p=0.7870

Primary: Number of Participants With Adverse Events (AEs) by Severity Grade and Study Drug Treatment-emergent Adverse Events (TEAEs) — 11; 32; 32; 0 Participants

Primary: Mean Change From Baseline in Pruritus Symptoms, as Measured by the 24-hour Average Pruritus Visual Analogue Scale (VAS) Score — -41.5; -35.8 score on a scale

Primary: Proportion of Study Subjects Able to Titrate up to the Maximum Tolerated Dose — 6 Participants

Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale

Primary: Rate of Renal Transplant Rejection (Cohort 2) or GVHD (Cohort 1). — 0 Percentage of participants

Primary: Number of Participants With Adverse Events — 5; 1 participants

Primary: Objective Response Rate (ORR) According to the Revised Response Criteria for Malignant Lymphoma (Parts A, B, and C) — 93; 95; 85 Percentage of participants

Primary: Objective Response Rate — 0; 7; 6 Participants

Primary: Progression-free Survival (PFS) — 5.257 months

Primary: Mean Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) [Friedewald] — -5.48; -37.97; -43.35 percent change from baseline — p=<.0001

Primary: Number of Participants With ≥1 Adverse Event (AE) — 17; 23; 90; 3 Participants

Primary: Change From Baseline to Endpoint (Day 28 or Early Termination) in Visual Analogue Scale (VAS) Pruritus 24 Hour Average Intensity. — -40.5; -36.5 mm

Primary: Participants With a Response — 9 Participants

Primary: Physician Global Assessment (PGA) of Skin Overall Response — 5; 5; 0; 0 Participants